| Russell, David |
| Recruiting | 4 | 30 | US | Furosemide (plus potassium chloride), Placebo (plus placebo electrolyte solution) | Children's Hospital Medical Center, Cincinnati, Rainbow Babies and Children's Hospital, Emory University, RTI International, National Heart, Lung, and Blood Institute (NHLBI) | Bronchopulmonary Dysplasia | 09/25 | 09/25 | | |
| Recruiting | 3 | 1200 | Europe, Canada, Japan, US, RoW | Remternetug, LY3372993, Placebo | Eli Lilly and Company | Alzheimer's Disease | 04/29 | 10/30 | | |
| Active, not recruiting | 3 | 1667 | Japan, US | Remternetug (IV), LY3372993, Remternetug (SC), Placebo | Eli Lilly and Company | Alzheimer's Disease | 06/24 | 03/26 | | |
ENVISION, NCT05310071: A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease |
|
|
| Terminated | 3 | 1027 | Europe, Canada, Japan, US, RoW | Aducanumab, BIIB037, Aducanumab-avwa, Aduhelm, Placebo | Biogen | Alzheimer's Disease | 08/24 | 08/24 | | |
NCT05026866: A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3) |
|
|
| Active, not recruiting | 3 | 2196 | Japan, US | Donanemab, LY3002813, Placebo | Eli Lilly and Company | Alzheimer Disease | 11/27 | 11/27 | | |
| Completed | 2 | 23 | US | [18F] PI-2620 | Michael J. Fox Foundation for Parkinson's Research, Institute for Neurodegenerative Disorders | Parkinson Disease | 01/23 | 02/23 | | |
NCT00387075: A Study Evaluating Potential Screening Tools for Detecting Parkinson Disease |
|
|
| Active, not recruiting | 2 | 3000 | US | [123I]β-CIT and SPECT imaging, [123I]β-CIT | Institute for Neurodegenerative Disorders, United States Department of Defense, Molecular NeuroImaging | Parkinson Disease | 08/23 | 08/23 | | |
| Recruiting | 2 | 78 | Canada, US | Remote ischemic conditioning (RIC) + Standard of Care for NEC, Standard of Care for NEC | The Hospital for Sick Children, Thrasher Research Fund, Mount Sinai Hospital, Canada, Sunnybrook Health Sciences Centre, McMaster Children's Hospital, Children's Hospital Medical Center, Cincinnati, Children's Hospital of Orange County, Karolinska University Hospital, Sophia Kindergeneeskunde, UCL Great Ormond Street Institute of Child Health, Hospital Universitario La Paz, University of Southampton | Necrotizing Enterocolitis | 02/27 | 05/27 | | |
NCT04141150: Evaluation of [18F]APN-1607 PET Uptake in Alzheimer's Disease Patients Compared With Healthy Subjects |
|
|
| Active, not recruiting | 2 | 130 | US | [18F]APN-1607 | APRINOIA Therapeutics, LLC | Alzheimer's Disease, Mild Cognitive Impairment Due to Alzheimer's Disease, Healthy Volunteers | 09/24 | 02/25 | | |
LUMA, NCT05348785: A Study to Assess the Safety of BIIB122 Tablets and if it Can Slow the Worsening of Early-Stage Parkinson's Disease in Participants Between the Ages of 30 and 80 |
|
|
| Recruiting | 2 | 640 | Europe, Canada, Japan, US, RoW | BIIB122, DNL151, BIIB122-Matching Placebo | Biogen, Denali Therapeutics Inc. | Parkinson Disease | 12/25 | 12/25 | | |
NCT06445465: Study to Evaluate a Potential PET Radioligand for Imaging Alpha-synuclein Deposits in the Brain |
|
|
| Active, not recruiting | 1 | 30 | US | [18F]MNI-1216, [18F]ACI-12589 | Invicro, AC Immune SA | Alpha-Synucleinopathy, Parkinson's Disease, Dementia With Lewy Bodies, Multisystem Atrophy | 07/24 | 08/24 | | |
NCT05164536: Plasma P-tau2017 and Quantitative Amyloid PET Imaging |
|
|
| Recruiting | 1 | 200 | US | Amyvid, [18F]Florbetapir | Invicro | Alzheimer Disease | 09/22 | 09/22 | | |
| Completed | 1 | 10 | US | LY3857210 | Eli Lilly and Company | Healthy | 12/22 | 12/22 | | |
NCT05274568: Proof of Mechanism Study to Evaluate Binding of Alfa-synuclein |
|
|
| Recruiting | 1 | 14 | US | [18F]UCB-2897 | Invicro | Parkinson Disease, Multisystem Atrophy, Healthy Volunteer | 12/22 | 12/22 | | |
NCT05775601: 18F-LY3950321-01 Biodistribution and Safety Study |
|
|
| Completed | 1 | 6 | US | 18F-LY3950321, 18F-MNI-1256, PET Scan | Avid Radiopharmaceuticals | Diagnostic Agent Adverse Reaction, Radiation Exposure | 04/23 | 04/23 | | |
| Recruiting | 1 | 18 | US | [18F] APN-1607 | Invicro | Progressive Supranuclear Palsy, Healthy Volunteers | 06/24 | 06/24 | | |
| Active, not recruiting | N/A | 60 | Europe | | The Leeds Teaching Hospitals NHS Trust | Diabetic Foot, Diabetic Foot Ulcer | 04/24 | 04/24 | | |
NCT04507139: Early Longitudinal Imaging in Parkinson's Progression Markers Initiative Using [¹⁸F] AV-133 and DaTscan™ |
|
|
| Active, not recruiting | N/A | 50 | US | | Michael J. Fox Foundation for Parkinson's Research | Parkinson Disease | 06/25 | 06/25 | | |
| Recruiting | N/A | 4500 | Europe, Canada, US, RoW | | Michael J. Fox Foundation for Parkinson's Research, Institute for Neurodegenerative Disorders | Parkinson Disease | 12/33 | 12/33 | | |
| Yokum, Kelley |
| Active, not recruiting | 3 | 800 | Europe, US | Donanemab, LY3002813, Placebo | Eli Lilly and Company | Alzheimer's Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders | 05/24 | 05/25 | | |
NCT05026866: A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3) |
|
|
| Active, not recruiting | 3 | 2196 | Japan, US | Donanemab, LY3002813, Placebo | Eli Lilly and Company | Alzheimer Disease | 11/27 | 11/27 | | |
NCT05686044: A Dose-ranging Study to Investigate Efficacy of Buntanetap in Mild to Moderate AD |
|
|
| Completed | 2/3 | 320 | US | Buntanetap/Posiphen, Posiphen Tartrate, Placebo | Annovis Bio Inc. | Alzheimer Disease | 02/24 | 02/24 | | |
NCT05729373: A Clinical Study That Will Measure How Well SEP-363856 Works and How Safe it is in Adults With Generalized Anxiety Disorder |
|
|
| Recruiting | 2/3 | 434 | Europe, Japan, US | SEP-363856, Placebo | Otsuka Pharmaceutical Development & Commercialization, Inc. | Generalized Anxiety Disorder | 02/25 | 02/25 | | |
NCT04279522: The MOOD Study - External Combined Occipital and Trigeminal Nerve Stimulation (eCOT-NS) for the Treatment of Major Depressive Disorder (MDD) |
|
|
| Completed | N/A | 126 | US, RoW | Relivion®DP- Active, Relivion®DP- Sham | Neurolief Ltd. | MDD | 06/24 | 06/24 | | |
| Feinberg, Marc |
| Completed | 3 | 507 | Europe, US, RoW | Tavapadon, PF-06649751, CVL-751, Placebo | Cerevel Therapeutics, LLC | Parkinson Disease | 01/24 | 02/24 | | |
NCT06298552: A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients with Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis |
|
|
| Recruiting | 3 | 110 | Europe, US, RoW | Efgartigimod IV, Placebo IV | argenx | Generalized Myasthenia Gravis | 07/25 | 07/27 | | |
MyClad, NCT06463587: Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis |
|
|
| Recruiting | 3 | 240 | Europe, Japan, US, RoW | Placebo, Cladribine Low Dose, Cladribine High Dose | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany, EMD Serono Research & Development Institute, Inc. | Generalized Myasthenia Gravis | 05/28 | 07/30 | | |
NIMBLE, NCT05070858 / 2020-003272-41: A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis |
|
|
| Recruiting | 3 | 235 | Europe, Canada, Japan, US, RoW | Pozelimab + Cemdisiran, Cemdisiran, ALN-CC5, Placebo, Pozelimab, REGN3918 | Regeneron Pharmaceuticals | Generalized Myasthenia Gravis | 05/25 | 03/28 | | |
| Recruiting | 3 | 124 | US | Efgartigimod PH20 SC, Placebo PH20 SC | argenx | Myasthenia Gravis, Ocular | 12/25 | 12/27 | | |
| Completed | 3 | 304 | Europe, US, RoW | Tavapadon, PF-06649751, CVL-751, Placebo | Cerevel Therapeutics, LLC | Parkinson Disease | 10/24 | 10/24 | | |
| Recruiting | 3 | 800 | Europe, Canada, Japan, US, RoW | Remibrutinib, LOU064, Teriflunomide | Novartis Pharmaceuticals, Novartis Pharma AG | Relapsing Multiple Sclerosis | 04/26 | 10/30 | | |
NCT05026866: A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3) |
|
|
| Active, not recruiting | 3 | 2196 | Japan, US | Donanemab, LY3002813, Placebo | Eli Lilly and Company | Alzheimer Disease | 11/27 | 11/27 | | |
NCT04146051: Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG) |
|
|
| Recruiting | 2 | 30 | Canada, US | Descartes-08 | Cartesian Therapeutics | Myasthenia Gravis, Generalized | 03/25 | 03/26 | | |
NCT06006247: Early Parkinson's Disease Monotherapy With CVN424 |
|
|
| Active, not recruiting | 2 | 62 | US | CVN424 150 mg, Placebo | Cerevance Beta, Inc. | Parkinson's Disease | 10/24 | 02/25 | | |
| Medina, Jorge A |
| Active, not recruiting | 3 | 800 | Europe, US | Donanemab, LY3002813, Placebo | Eli Lilly and Company | Alzheimer's Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders | 05/24 | 05/25 | | |
| Active, not recruiting | 3 | 1667 | Japan, US | Remternetug (IV), LY3372993, Remternetug (SC), Placebo | Eli Lilly and Company | Alzheimer's Disease | 06/24 | 03/26 | | |
NCT05976243: A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines |
|
|
| Recruiting | 3 | 348 | Europe, Canada, Japan, US, RoW | Remibrutinib, Placebo | Novartis Pharmaceuticals | Chronic Inducible Urticaria | 07/26 | 12/28 | | |
NCT05513001 / 2022-001034-11: An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib |
|
|
| Active, not recruiting | 3 | 694 | Europe, Canada, Japan, US, RoW | LOU064 (blinded), remibrutinib, Placebo, LOU064 (open label) | Novartis Pharmaceuticals | Chronic Spontaneous Urticaria | 02/27 | 02/27 | | |
NCT05026866: A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3) |
|
|
| Active, not recruiting | 3 | 2196 | Japan, US | Donanemab, LY3002813, Placebo | Eli Lilly and Company | Alzheimer Disease | 11/27 | 11/27 | | |
| Active, not recruiting | 2/3 | 225 | Canada, US | Piromelatine 20 mg, Neu-P11, Placebo | Neurim Pharmaceuticals Ltd., Syneos Health | Alzheimer's Disease | 06/25 | 06/25 | | |
POSCOL, NCT04663581: Comparison Between the Right Lateral Decubitus and the Left Lateral Decubitus as Starting Position in Colonoscopy |
|
|
| Recruiting | N/A | 167 | RoW | Left Sided Colonoscopy, Right Sided Colonoscopy | Sanitas University | Colonoscopy | 02/21 | 03/21 | | |
| Recruiting | N/A | 50 | Europe | ESP Block, Erector spinae Plane Block, Morphine injection, Intravenous opioid infusion analgesia and paracetamol | Hospital Clinic of Barcelona | Heart Valve Diseases, Postoperative Pain, Acute, Analgesia | 03/24 | 06/24 | | |
NCT05569005: Effect of Switching From Cigarette Smoking to THS on Disease Progression in Mild to Moderate COPD Subjects With Chronic Bronchitis Symptoms. |
|
|
| Terminated | N/A | 715 | Europe, Japan, US, RoW | THS use, Tobacco Heating System 3.0, Cigarette, Smoking Abstinence | Philip Morris Products S.A. | COPD, Smoking, Tobacco Use | 09/24 | 09/24 | | |
| Luffman, Angi |
ALTITUDE-AD, NCT06335173: A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants with Early Alzheimer's Disease |
|
|
| Recruiting | 2 | 540 | Europe, Canada, US | sabirnetug, Placebo | Acumen Pharmaceuticals | Alzheimer Disease | 10/26 | 10/26 | | |
| Martinez, Andrew |
ALTITUDE-AD, NCT06335173: A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants with Early Alzheimer's Disease |
|
|
| Recruiting | 2 | 540 | Europe, Canada, US | sabirnetug, Placebo | Acumen Pharmaceuticals | Alzheimer Disease | 10/26 | 10/26 | | |
